

Healthcare Common Procedure Coding System Quarterly Update

Effective July 1, 2022

The Centers for Medicare and Medicaid Services (CMS) publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the "[HCPCS Quarterly Update](#)" page. Be sure to update any systems accordingly.

Proprietary Lab Analyses (PLA)

- 0324U Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug
- 0325U Oncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug
- 0329U Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations
- 0331U Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations

Drugs

New HCPCS Codes

- C9095 Injection, Tebentafusp-tebn, 1 mcg
- C9096 Injection, filgrastim-ayow (Releuko), 1 mcg
- C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- J9331 Sirolimus protein-bound particles, 1 mg

Pass-Through Status Change

No pass-through status changes identified in oncology related HCPCS codes.

Discontinued HCPCS codes

- C9091 Injection, sirolimus protein-bound particles, 1 mg